Cardiovascular risk associated with the use of cannabis and cannabinoids: a systematic review and meta-analysis
Authors' conclusion
The findings reveal positive associations between cannabis use and MACE.
Study context
- Population
- Pharmacoepidemiological studies of cannabis or cannabinoid use and major adverse cardiovascular events (MACE), published 2016–202324 studies
- Comparison
- Cannabis use vs no cannabis use
- Outcome
- MACE:
- CV death
- Non-fatal ACS including myocardial infarction (MI)
- Non-fatal stroke
Methodological detailsrandom-effects model, 17 cross-sectional, 6 cohort and 1 case-control study; quality by ROBINS-E
- Random-effects model
- 17 cross-sectional, 6 cohort and 1 case-control study; quality by ROBINS-E
Pooled result
As reported in the abstract
MACE components (ACS, stroke, CV death), cannabis use
Pooled RR, acute coronary syndrome (ACS)
1.29
95% CI 1.05 to 1.59
Pooled RR, stroke
1.20
95% CI 1.13 to 1.26
Pooled RR, CV death
2.10
95% CI 1.29 to 3.42
Further pooled results
Composite of ACS and stroke (2 studies)
- No statistically significant association
Cohort studies only (focused analysis)
- Pooled RR (1.01 to 1.73), comparable to primary model
- 1.32
Original publication
Cardiovascular risk associated with the use of cannabis and cannabinoids: a systematic review and meta-analysis. Heart. Published 17 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →